Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) announced a proposed private offering of $115 million aggregate principal of Convertible Senior Notes due 2034, with an initial purchaser option for an additional $15 million. Ocugen intends to use approximately $32.7 million of net proceeds to repay a loan and related fees; remaining proceeds for general corporate purposes. Terms including interest rate and conversion rate will be set at pricing. Notes will be unsecured, rank junior to secured debt to the extent of secured assets, and may be converted into cash, shares, or a combination at Ocugen's election. The offering is to qualified institutional buyers under Rule 144A and is subject to market conditions.
Positive
- Proceeds of $115M (plus $15M option) provide near-term liquidity
- Approximately $32.7M allocated to repay existing loan and related fees
- Use of remaining proceeds reserved for general corporate purposes
Negative
- Convertible notes may dilute shareholders if converted into common stock
- Notes are unsecured and rank junior to secured indebtedness to the extent of secured assets
- Offering completion is uncertain and subject to market and other conditions
News Market Reaction – OCGN
In the May 5 session, OCGN declined 19.46%, reflecting a significant negative market reaction. Argus tracked a trough of -21.1% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Earnings call notice | Neutral | +1.2% | Scheduled call and webcast to discuss Q1 2026 results and business updates. |
| Apr 23 | Conference participation | Neutral | -0.6% | Presentations at investor and industry conferences highlighting modifier gene therapy platform. |
| Apr 01 | Clinical progress | Positive | -1.1% | Early completion of dosing in Phase 2/3 pivotal GARDian3 trial for OCU410ST. |
| Mar 24 | Clinical data update | Positive | -8.6% | Positive 12‑month Phase 2 ArMaDa data for OCU410 in geographic atrophy with lesion reduction. |
| Mar 23 | Webcast announcement | Neutral | +2.9% | Announcement of webcast to review full Phase 2 ArMaDa clinical trial data for OCU410. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical catalysts often saw negative next-day reactions, while logistical or event-related news produced smaller, mixed moves.
This announcement follows several months of pipeline and corporate updates. In March–April 2026, Ocugen reported positive Phase 2 data for OCU410 in geographic atrophy and early completion of dosing in the Phase 2/3 GARDian3 trial for OCU410ST, yet shares fell after those clinical releases. Conference participation and webcast announcements in late March and late April saw modest price gains or small declines. Today’s financing news comes after these development milestones and investor outreach efforts.
Key Terms
convertible senior notes financial
Rule 144A regulatory
general unsecured obligations financial
accrued and unpaid interest financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other factors,
Ocugen intends to use approximately
The notes will be Ocugen’s general unsecured obligations and will rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to all of its existing and future liabilities that are not so subordinated, and junior to all of its secured indebtedness, to the extent of the value of the assets securing such indebtedness. Interest will be payable semi-annually in arrears. The notes may be converted into cash, shares of Ocugen’s common stock or a combination thereof, at Ocugen’s election. The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.
The notes will only be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the notes nor the shares of Ocugen’s common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including but not limited to, statements regarding the proposed terms of the notes; the anticipated terms of the notes; the size of the offering, including the initial purchaser’s option to purchase additional notes; the anticipated use of proceeds from the offering, including the repayment of the existing loan facility; the completion of the offering, and other statements contained in this press release that are not historical facts. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to: uncertainties related to market conditions and whether the offering will be completed on the anticipated terms or at all; the impact of the offering on the market price of Ocugen’s common stock; risks related to the potential dilution to holders of Ocugen’s common stock; and uncertainties regarding the conversion price and other terms of the notes. These and other risks and uncertainties are more fully described in Ocugen’s periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
